| Phase of Development |
NRTI |
NNRTI |
PI |
EI* |
Integrase Inhibitors |
Maturation Inhibitors |
Other |
| Preclinical |
BPH-218, biphosphonate NRTI, U Pittsburgh |
Diarylpyrimidines, Tibotec |
GS-9005, Gilead |
Benzothiepine and Benzazepine derivatives, CCR5 antagonists, Takeda |
L-870812, MSD |
enJS56A1, Escape Inhibitor, U Georgia |
RWJ67567, p38 inhibitor, U Penn / J&J |
|
Dinucleoside polyphosphates, NRTI "potentiators", U Miami |
NVP C-8 derivatives, BI |
VX-385, GSK/Vertex |
Betulinic Acid Derivatives (BAD), U North Carolina |
Carbazole derivative, NIID |
PA-457, Budding inhibitor, Panacos |
ACH-CIP, capsid inhibitor, Achillion |
|
siRNA molecule, CombiMatrix |
Tricyclic NNRTI, BMS |
AG-1859, Pfizer |
KRH-2731, X4 antagonist, Kureha |
810871, GSK |
Chloroquine, Catholic U, Rome |
a TRIM5, capsid inhibitor, Dana Farber, NIAID |
|
GS7340, TDF prodrug, Gilead |
SMP-717, Advanced Life Sciences |
|
PRO-140, monoclonal antibody (MAb), Progenics |
Styrylquinoline, Bioalliance Pharma |
Betulinic Acid Derivatives (BAD), U North Carolina |
CDK inhibitor, Gilead |
|
|
SMP-610, Advanced Life Sciences |
|
GBV-C, virus that increases chemokines including RANTES (CCR5 blocker), U Iowa |
V-165, Rega Institute, Belgium |
|
Mifepristone, glucocorticoid antagonist, U Pittsburgh |
|
|
695634, GSK |
|
15K, co-receptor docking inhibitor, NCI |
|
|
RSC-1838, GSK/Shionogi |
|
|
|
|
15D, co-receptor docking inhibitor, NCI |
|
|
siRNA molecule, Nef inhibitor, CombiMatrix |
|
|
|
|
ONO-4128, CCR5 antagonist, GSK/ONO |
|
|
Resveretol, Egr1 gene activator, NCI |
|
|
|
|
D5, artificial MAb, MSD |
|
|
|
| Phase I |
SPD-754, Shire Biochem |
|
PL-100, Procyon BioPharma |
AMD-070, CXCR4 antagonist, Anormed |
|
|
HGTV43, gene regulation/editing inhibitor, Enzo |
|
|
|
|
AMD-887, CCR5 antagonist, Anormed |
|
|
Mycophenylate mofetil, immunosuppressant, U Barcelona |
|
|
|
|
GSK-873140, GSK |
|
|
VRX496
lentiviral vector
VIRxSYS Corp |
| Phase I/II or Phase IB |
MIV-210 (FGV), Medivir/GSK |
|
|
BMS-043, anti-gp120 blocker, BMS |
|
|
BAY 50-4798, IL2 selective agonist, Bayer |
|
Reverset (D-D4FC), Pharmasset/Incyte |
|
|
SCH D, CCR5 antagonist, Schering Plough |
|
|
|
|
SN-1212/1461, mutagenic deoxyribonucleoside, Koronis |
|
|
SP-01A, Entry Inhibitor, Samaritan Pharma |
|
|
|
|
Racivir (PSI 5004), Pharmasett |
|
|
TNX-355, Anti-CD4 MAb, Tanox/Biogen |
|
|
|
| Phase II |
Elvucitabine (ACH-126), Achillion |
Calanolide A, Advanced Life Sciences |
TMC-114/r, Tibotec/J&J |
PRO-542, attachment inhibitor, Progenics |
|
|
|
|
Amdoxovir (DAPD), Emory University |
TMC-125 (etravirine), Tibotec/J&J |
|
UK-427,857, CCR5 antagonist, Pfizer |
|
|
|
|
Alovudine (MIV-310), Medivir/BI |
|
|
|
|
|
|
| Phase III |
|
Capravirine/r, Pfizer/Agouron |
Tipranavir/r, Boehringer Ingelheim |
|
|
|
|
Notes: EI = entry inhibitors, including CCR5 and CXCR4 receptor binding antagonists and CD4 monoclonal antibodies directed at binding, fusion, and entry.
possibly on hold
Recent news from the XIth Conference on Retroviruses and Opportunistic Infections, San Francisco, 8-11 February, 2004 |
|